Interaction of St John's wort (Hypericum perforatum) with clozapine

International Clinical Psychopharmacology

Volumn 27, Issue 2, 2012, Pages 121-123

  Van Strater, Annelies C P ^a   Bogers, Jan P A M ^b  

^a Mental Health Services Duin en Bollenstreek   (Netherlands)

^b Psychiatric Centre Rivierduinen   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CYTOCHROME P450; GLYCOPROTEIN P; HYPERICUM PERFORATUM EXTRACT; NON PRESCRIPTION DRUG;

ADULT; ARTICLE; CASE REPORT; DISORIENTATION; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; ENZYME INDUCTION; FEMALE; HEBEPHRENIA; HERB DRUG INTERACTION; HUMAN; HYPERICUM PERFORATUM; MENTAL DISEASE; PHYSICIAN; PRIORITY JOURNAL; PROTEIN INDUCTION; SCHIZOPHRENIA; SELF MEDICATION;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DRUG RESISTANCE; FEMALE; HERB-DRUG INTERACTIONS; HUMANS; HYPERICUM; PLANT PREPARATIONS; SCHIZOPHRENIA, DISORGANIZED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84856422826     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32834e8afd     Document Type: Article

References (32)

1. Bauer S, Störmer E, Johne A, Krüger H, Budde K, Neumayer HH, et al. (2003). Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol 55:203-211. (Pubitemid 36237867)
2. Bebawy M, Chetty M (2008). Differential pharmacological regulation of drug efflux and pharmacoresistant schizophrenia. BioEssays 30:183-188. (Pubitemid 351196953)
3. Borrelli F, Izzo AA (2009). Herb-drug interactions with St John'sWort (Hypericum perforatum): an update on clinical observations. AAPS J 11:710-727.
4. Butterweck V, Derendorf H (2008). Potential of pharmacokinetic profiling for detecting herbal interactions with drugs. Clin Pharmacokinet 47:383-397. (Pubitemid 351685388)
5. Chetty M, Murray M (2007). CYP-mediated clozapine interactions: how predictable are they? Curr Drug Metab 8:307-313. (Pubitemid 46780060)
6. Clozapine Collaboration Group (2009). Guideline for the use of clozapine. www.clozapinepluswerkgroep.nl.
7. Colalto C (2010). Herbal interactions on absorption of drugs: mechanismes of action and clinical risk assessment. Pharmacol Res 62:207-227.
8. Cott JM (2001). Herb-drug interactions: focus on pharmacokinetics. CNS Spectr 6:827-832. (Pubitemid 34027305)
9. Cozza KL, Armstrong SC, Oesterheld JR (2003). Concise guide to drug interaction principles for medical practice. 2nd ed. Washington: American Psychiatric Publishing. pp. 362-364.
10. Di YM, Li CG, Xue CC, Zhou SR (2008). Clinical drugs that interact with St John's Wort and implication in drug development. Curr Pharm Des 14: 1723-1742. (Pubitemid 351998596)
11. El Ela AA, Härtter S, Schmitt U, Hiemke C, Spahn-Langguth H, Langguth P (2004). Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds - implications for pharmacokinetics of selected substrates. J Pharm Pharmacol 56:967-975. (Pubitemid 39140051)
12. Fromm MF (2003). Importance of p-glycoprotein for drug disposition in humans. Eur J Clin Invest 33 (S2):6-9.
13. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P (2002). St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. J Clin Psychopharmacol 54:349-356. (Pubitemid 35334946)
14. Izzo AA, Ernst E (2009). Interaction between herbal medicines and prescribed drugs. An updated systematic review. Drugs 69:1777-1798.
15. Karyekar CS, Eddington ND, Dowling TC (2002). Effects of St John's Wort extract on intestinal expression of cytochrome P4501A2 studies in LS180 cells. J Postgrad Med 48:97-100. (Pubitemid 35012358)
16. Kober M, Pohl K, Efferth T (2008). Molecular mechanisms underlying St John's Wort drug interactions. Curr Drug Metab 9:1027-1037.
17. Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V (2006). Hyperforine in St John's wort drug interactions. Eur J Clin Pharmacol 62:225-233. (Pubitemid 43357581)
18. Mannell M (2004). Drug interactions with St John's Wort. Mechanisms and clinical implications. Drug Saf 27:773-797.
19. Miller LG (2001). Drug interactions known or potentially associated with St John's Wort. J Herb Pharmacother 1:51-64. (Pubitemid 32998316)
20. Murray M (2006). Role of CYP pharmacogenetics and drug-drug interactions in the efficacy and safety of atypical and other antipychotic agents. J Pharm Pharmacol 58:871-885. (Pubitemid 43967103)
21. Nebel A, Schneider BJ, Baker RK, Kroll DJ (1999). Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 33:502. (Pubitemid 29215819)
22. Nowack R (2008). Review article: cytochrome P450 enzyme and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's Wort - and beyond! Nephrology 13:337-347. (Pubitemid 351668338)
23. Pal D, Mitra AK (2006). MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 78:2131-2145.
24. Prior TI, Baker GB (2003). Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 28: 99-112. (Pubitemid 36628196)
25. Sandson NB, Armstrong SC, Cozza KL (2005). An overview of psychotropic drug-drug interactions. Psychosomatics 46:464-494. (Pubitemid 46177967)
26. Saxena A, Tripathi KP, Roy S, Khan F, Sharma A (2008). Pharmacovigilance: effects of herbal components on human drugs interactions involving cytochrome P450. Bioinformation 3:198-204.
27. Singh YN (2005). Potential for interaction of kava and St. John's wort with drugs. J Ethnopharmacol 100:108-113. (Pubitemid 41073531)
28. Sirot EJ, Knezevic B, Morena GP, Harenberg S, Oneda B, Crettol S, et al. (2009). ABCB1 and cytochrome P450 polymorphisms. Clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 29:319-326.
29. Tian R, Koyabu N, Morimoto S, Shoyama Y, Ohtani H, Sawada Y (2005). Functional induction and de-induction of p-glycoprotein bij St. John's Wort ant its ingredients in a human colon adenocarcinoma cell line. Drug Metab Dispos 33:547-554. (Pubitemid 40393198)
30. Urichuk L, Prior TI, Dursun S, Baker G (2008). Metabolism of atypical antipsychotics: involvement of cytochrome P450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 9:410-418. (Pubitemid 352025195)
31. Zhang W, Han Y, Lim SL, Lim LY (2009). Dietary regulation of P-gp function and expression. Expert Opin Drug Metab Toxicol 5:789-801.
32. Zhou S, Lai X (2008). An update on clinical drug interactions with the herbal antidepressant St John's Wort. Curr Drug Metab 9:394-409. (Pubitemid 352025194)